Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Gov. Gavin Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost ...

Fourth-quarter earnings at JPMorgan Chase, Wells Fargo, Goldman Sachs, and Citigroup beat analysts’ estimates.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

“The term osteoporosis screening refers to use of bone density, x-ray studies or other tools to identify persons at an increased risk of fractures or bone breaks,” Dr. Thomas Weber, an endocrinologist ...